Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (Hardback)
5 Angebote vergleichen
Bester Preis: € 52,56 (vom 01.10.2020)1
Symbolbild
Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (Hardback) (2020)
~EN HC NWISBN: 9783039430901 bzw. 3039430904, vermutlich in Englisch, MDPI AG, United States, gebundenes Buch, neu.
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom.
Language: English. Brand new Book. Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.
Language: English. Brand new Book. Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.
2
Symbolbild
Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (2017)
~EN PB NW RPISBN: 9783039430901 bzw. 3039430904, vermutlich in Englisch, MDPI AG, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, Ria Christie Collections [59718070], Uxbridge, United Kingdom.
PRINT ON DEMAND Book; New; Publication Year 2017; Fast Shipping from the UK.
PRINT ON DEMAND Book; New; Publication Year 2017; Fast Shipping from the UK.
4
Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges (2020)
EN HC NWISBN: 9783039430901 bzw. 3039430904, in Englisch, 260 Seiten, Müller, Rüdiger, Mdpi AG, gebundenes Buch, neu.
Lieferung aus: Deutschland, Derzeit nicht auf Lager. Bestellen Sie jetzt und wir liefern, sobald der Artikel verfügbar ist. Sie erhalten von uns eine E-Mail mit dem voraussichtlichen Lieferdatum, sobald uns diese Information vorliegt. Lieferung von Amazon, Versandkostenfrei.
Von Händler/Antiquariat, Amazon.de.
Mdpi AG, Gebundene Ausgabe, Publiziert: 2020-09-16T00:00:01Z, Produktgruppe: Book.
Von Händler/Antiquariat, Amazon.de.
Mdpi AG, Gebundene Ausgabe, Publiziert: 2020-09-16T00:00:01Z, Produktgruppe: Book.
5
Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges MDPI AG Author
~EN HC NWISBN: 9783039430901 bzw. 3039430904, vermutlich in Englisch, Mdpi AG, gebundenes Buch, neu.
Lieferung aus: Vereinigte Staaten von Amerika, Lagernd, zzgl. Versandkosten.
Rheumatoid Arthritis Therapy Reappraisal,Mdpi AG.
Rheumatoid Arthritis Therapy Reappraisal,Mdpi AG.
Lade…